Literature DB >> 35324190

Synthesis and Characterization of Transition-State Analogue Inhibitors against Human DNA Methyltransferase 1.

Farah Lamiable-Oulaidi1, Rajesh K Harijan2, Karl J Shaffer1, Douglas R Crump1, Yan Sun2, Quan Du2, Shivali A Gulab1, Ashna A Khan1, Andreas Luxenburger1, Anthony D Woolhouse1, Simone Sidoli2, Peter C Tyler1, Vern L Schramm2.   

Abstract

Hypermethylation of CpG regions by human DNA methyltransferase 1 (DNMT1) silences tumor-suppression genes, and inhibition of DNMT1 can reactivate silenced genes. The 5-azacytidines are approved inhibitors of DNMT1, but their mutagenic mechanism limits their utility. A synthon approach from the analogues of S-adenosylhomocysteine, methionine, and deoxycytidine recapitulated the chemical features of the DNMT1 transition state in the synthesis of 16 chemically stable transition-state mimics. Inhibitors causing both full and partial inhibition of purified DNMT1 were characterized. The inhibitors show modest selectivity for DNMT1 versus DNMT3b. Active-site docking predicts inhibitor interactions with S-adenosyl-l-methionine and deoxycytidine regions of the catalytic site, validated by direct binding analysis. Inhibitor action with purified DNMT1 is not reflected in cultured cells. A partial inhibitor activated cellular DNA methylation, and a full inhibitor had no effect on cellular DNA methylation. These compounds provide chemical access to a new family of noncovalent DNMT chemical scaffolds for use in DNA methyltransferases.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35324190      PMCID: PMC9205225          DOI: 10.1021/acs.jmedchem.1c01869

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  42 in total

1.  Synthesis of DNA oligonucleotides containing 5-(mercaptomethyl)-2'-deoxyuridine moieties.

Authors:  Benjamin Bornemann; Andreas Marx
Journal:  Bioorg Med Chem       Date:  2006-06-13       Impact factor: 3.641

Review 2.  Discovery and development of DNA methyltransferase inhibitors using in silico approaches.

Authors:  José L Medina-Franco; Oscar Méndez-Lucio; Alfonso Dueñas-González; Jakyung Yoo
Journal:  Drug Discov Today       Date:  2014-12-16       Impact factor: 7.851

Review 3.  Targeting DNA methylation with small molecules: what's next?

Authors:  Alexandre Erdmann; Ludovic Halby; Jacques Fahy; Paola B Arimondo
Journal:  J Med Chem       Date:  2014-12-04       Impact factor: 7.446

Review 4.  DNA Methyltransferase Inhibitors and their Therapeutic Potential.

Authors:  Zehao Zhou; Huan-Qiu Li; Feng Liu
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 5.  Clinical development of demethylating agents in hematology.

Authors:  Shyamala C Navada; Juliane Steinmann; Michael Lübbert; Lewis R Silverman
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

6.  Crystal Structure of Human DNA Methyltransferase 1.

Authors:  Zhi-Min Zhang; Shuo Liu; Krystal Lin; Youfu Luo; John Jefferson Perry; Yinsheng Wang; Jikui Song
Journal:  J Mol Biol       Date:  2015-06-10       Impact factor: 5.469

7.  Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation.

Authors:  Jikui Song; Olga Rechkoblit; Timothy H Bestor; Dinshaw J Patel
Journal:  Science       Date:  2010-12-16       Impact factor: 47.728

Review 8.  DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.

Authors:  Jacques Fahy; Albert Jeltsch; Paola B Arimondo
Journal:  Expert Opin Ther Pat       Date:  2012-10-03       Impact factor: 6.674

9.  Fluorogenic Labeling of 5-Formylpyrimidine Nucleotides in DNA and RNA.

Authors:  Biswajit Samanta; Jan Seikowski; Claudia Höbartner
Journal:  Angew Chem Int Ed Engl       Date:  2015-12-17       Impact factor: 15.336

Review 10.  5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.

Authors:  Judith K Christman
Journal:  Oncogene       Date:  2002-08-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.